ArticlePharmacogenomics and personalized medicine2018
Meta-analysis of the association of the haptoglobin genotype with cardiovascular outcomes and the pharmacogenomic interactions with vitamin E supplementation.
Article in Pharmacogenomics and personalized medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 31 citations in OpenAlex.
- Impact of Vitamin E Supplementation on High-Density Lipoprotein in Patients With Haptoglobin Genotype-Stratified Diabetes: A Systematic Review of Randomized Controlled Trials.Journal of diabetes research · 2024Pooled it
- Haptoglobin phenotype and levels in type 2 diabetes and effects of fenofibrate.Journal of diabetes investigation · 2024Trial
- Effect of Anacetrapib on Cholesterol Efflux Capacity: A Substudy of the DEFINE Trial.Journal of the American Heart Association · 2020Trial
- Supplementation of Antioxidants in Chronic Kidney Disease: Clinical Necessity or Wishful Thinking? A Bench to Bedside Translational Research.Current medicinal chemistry · 2025Review
- Vitamin E (Alpha-Tocopherol) Metabolism and Nutrition in Chronic Kidney Disease.Antioxidants (Basel, Switzerland) · 2022Review
- An evaluation of the effects of ascorbic acid on the endothelium of coronary and aorta arteries in lead-intoxicated rabbits.SAGE open medicine · 2022Article
- Common and Novel Markers for Measuring Inflammation and Oxidative Stress Ex Vivo in Research and Clinical Practice-Which to Use Regarding Disease Outcomes?Antioxidants (Basel, Switzerland) · 2021Review
- The Role of Haptoglobin Polymorphism in Cardiovascular Disease in the Setting of Diabetes.International journal of molecular sciences · 2020Review
- Review
- Reflections of an aging free radical.Free radical biology & medicine · 2020Review
- Cardiovascular and Metabolic Protection by Vitamin E: A Matter of Treatment Strategy?Antioxidants (Basel, Switzerland) · 2020Review
- The Role of Nutrients in Reducing the Risk for Noncommunicable Diseases during Aging.Nutrients · 2019Review
- Biomarkers in Stress Related Diseases/Disorders: Diagnostic, Prognostic, and Therapeutic Values.Frontiers in molecular biosciences · 2019Review
- Article
- Precision Healthcare of Type 2 Diabetic Patients Through Implementation of Haptoglobin Genotyping.Frontiers in cardiovascular medicine · 2018Article
- Haptoglobin gene polymorphism and ischemic stroke: A case control study.Annals of Indian Academy of NeurologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThe objectives of the study were to compile and summarize the data from all of the clinical trials designed to examine the association between haptoglobin (Hp) genotype and incidence of cardiovascular (CV) events in patients with diabetes mellitus (DM) and to assess the impact of vitamin E treatment on CV outcomes according to the Hp genotype.
backgroundThe Hp genotype could serve as a predictive biomarker to DM patients who may benefit from vitamin E therapy.
methodsThe electronic databases MEDLINE, PubMed, EMBASE and the Cochrane Library for Central Register of Clinical Trials were searched systematically using the following MESH terms: "haptoglobin genotype", "diabetes mellitus" and "cardiovascular events".
resultsOverall, 13 studies fit the inclusion criteria for this analysis, yielding a large study population that included 6,161 patients without Hp 2-2 and 4,684 patients with Hp 2-2. The analysis of these studies showed that the incidence of CV events in DM patients with the Hp 2-2 genotype was significantly increased as compared to non-Hp 2-2 patients in all three subgroups of case-control (OR: 2.2, 95% CI: 1.3-3.6;
conclusionThe Hp genotype is a risk factor for CV events in patients with DM, and administration of vitamin E appears to offer a low cost and accessible means of reducing CV events and mortality in this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.